Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
复制标题
85例中危胃肠道间质瘤的回顾性分析
DOI：
10.18632/oncotarget.14359
复制
发表时间：
2017-02-07
期刊：
影响因子：
--
通讯作者：
Zhang X
中科院分区：
文献类型：
--
作者：
Fu Y;Hao H;Guo L;Yang G;Zhang X
伊马替尼辅助治疗高危胃肠道间质瘤（GIST）患者的显著获益已得到证实。然而，伊马替尼辅助治疗中危GIST的效果尚未得到充分研究。在这篇文章中，我们比较了接受伊马替尼辅助治疗和未接受伊马替尼辅助治疗的中危GIST患者的无复发生存率（RFS）的差异。在中国郑州大学第一附属医院进行了一项中危GIST的回顾性研究。手术治疗的112例患者的病理报告显示中等风险GIST。根据伊马替尼辅助治疗（≥1年）的给药情况设计治疗组和对照组。收集生存和复发数据，计算各组的RFS。对85例中危GIST患者进行随访。其中30例（治疗组）接受伊马替尼辅助治疗1年以上。通过比较两组的RFS，我们确定RFS率无统计学显著差异（P=0.940）。对于中危GIST患者来说，接受伊马替尼辅助治疗没有显着益处。
A significant benefit of imatinib adjuvant therapy for patients with high risk gastrointestinal stromal tumors (GIST) has been confirmed. However, the effect of imatinib adjuvant therapy for intermediate-risk GIST has not been well studied. In this article, we compare differences of recurrence-free survival (RFS) rates between patients with intermediate-risk GIST who accepted imatinib adjuvant therapy and those who did not. A retrospective study of intermediate-risk GIST was conducted in the First Affiliated Hospital of Zhengzhou University, China. The pathology reports of 112 patients who had been treated by surgery showed intermediate-risk GIST. The treatment and control groups were designed according to the administration of imatinib adjuvant therapy (≥1 year). Survival and recurrence data were collected and RFS of each group was calculated. Eighty fivepatients with intermediate-risk GIST were followed up. Thirty of them (treatment group) accepted imatinib adjuvant therapy over 1 year. Through comparing the RFS of the two groups, we established that there was no statistically significant difference in RFS rates (P=0.940). There is no significant benefit for patients with intermediate-risk GIST to accept imatinib adjuvant treatment.
影响因子：
3.3
作者：
Reichardt P;Blay JY;Mehren Mv
通讯作者：
Mehren Mv